Long‐term safety and efficacy of imeglimin as monotherapy or in combination with existing antidiabetic agents in Japanese patients with type 2 diabetes (TIMES 2): A 52‐week, open‐label, multicentre phase 3 trial

AIM: To evaluate the safety and efficacy of imeglimin for 52 weeks as monotherapy or combination therapy with existing antidiabetic agents in Japanese patients with type 2 diabetes. MATERIALS AND METHODS: TIMES 2 was a phase 3, pivotal, open‐label trial including patients with type 2 diabetes inadeq...

Descripción completa

Detalles Bibliográficos
Autores principales: Dubourg, Julie, Fouqueray, Pascale, Quinslot, Damien, Grouin, Jean‐Marie, Kaku, Kohei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9305103/
https://www.ncbi.nlm.nih.gov/pubmed/34866306
http://dx.doi.org/10.1111/dom.14613

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9305103/
https://www.ncbi.nlm.nih.gov/pubmed/34866306
http://dx.doi.org/10.1111/dom.14613

Ejemplares similares